CLPT Stock Analysis: Clearpoint Neuro | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 419m USD | 12M Return: 31.3% | US18507C1036 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.82M
Qual. Beats: -3
Rev. Trend: 98.9%
Qual. Beats: -1
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
ClearPoint Neuro, Inc. is a commercial-stage medical device company that develops and commercializes platforms for minimally invasive neurosurgical procedures, primarily in the United States. Its product portfolio includes the ClearPoint system, which combines hardware (head fixation frame, workstation, monitor), disposables (SmartFrame trajectory device, SmartFlow cannula), and software that assists physicians with surgical planning, navigation, and procedure monitoring. The company also offers the ClearPoint Prism Neuro laser therapy system for soft tissue ablation and the IRRAflow active fluid exchange system.
In addition to its device offerings, ClearPoint Neuro provides consulting and research services to pharmaceutical and medical technology partners, including preclinical studies, clinical trial support, and regulatory consultation. The company holds licensing and collaboration agreements with several partners, including Koninklijke Philips N.V., UCB Biopharma SRL, and Clinical Laserthermia Systems AB. It was formerly known as MRI Interventions, Inc., was incorporated in 1998, and is headquartered in Solana Beach, California.
- Pharma gene therapy partnerships accelerate drug delivery revenue growth
- ClearPoint Prism laser and IRRAflow drive new product adoption
- Capital raises likely as cash burn funds commercial expansion
| Net Income: -34.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.36 > 0.02 and ΔFCF/TA -17.44 > 1.0 |
| NWC/Revenue: 90.87% < 20% (prev 138.7%; Δ -47.83% < -1%) |
| CFO/TA -0.35 > 3% & CFO -30.2m > Net Income -34.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.73 > 1.5 & < 3 |
| Outstanding Shares: last quarter (29.9m) vs 12m ago 5.66% < -2% |
| Gross Margin: 62.61% > 18% (prev 60.42%; Δ 2.19% > 0.5%) |
| Asset Turnover: 56.52% > 50% (prev 53.43%; Δ 3.09% > 0%) |
| Interest Coverage Ratio: -7.63 > 6 (EBIT TTM -30.8m / Interest Expense TTM 4.04m) |
| A: 0.44 (Total Current Assets 48.7m - Total Current Liabilities 10.3m) / Total Assets 86.7m |
| B: -2.74 (Retained Earnings -237.8m / Total Assets 86.7m) |
| C: -0.41 (EBIT TTM -30.8m / Avg Total Assets 74.8m) |
| D: 0.14 (Book Value of Equity 10.8m / Total Liabilities 76.0m) |
| Altman-Z'' = -8.65 = D |
| DSRI: 1.74 (Receivables 9.36m/4.26m, Revenue 42.3m/33.6m) |
| GMI: 0.97 (GM 60.42% / 62.61%) |
| AQI: 22.53 (AQ_t 0.26 / AQ_t-1 0.01) |
| SGI: 1.26 (Revenue 42.3m / 33.6m) |
| TATA: -0.05 (NI -34.6m - CFO -30.2m) / TA 86.7m) |
| Beneish M = 10.50 (Cap -4..+1) = D |
As of September 23, 2026, the stock is trading at USD 15.79 with a total of 1,141,809 shares traded. Over the past week, the price has changed by +20.08%, over one month by +4.09%, over three months by -7.44% and over the past year by +31.26%.
Current recommended Stop Loss: 15.00 (which is 5% or 1.2 ATR below the current price).
Clearpoint Neuro has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy CLPT.
- StrongBuy: 2
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 23.5 | 48.8% |
P/E Forward = 12.1065
P/S = 9.9134
P/B = 37.9321
P/EG = 0.605
Revenue TTM = 42.3m USD
EBIT TTM = -30.8m USD
EBITDA TTM = -27.4m USD
Long Term Debt = 50.2m USD (from longTermDebt, last quarter)
Short Term Debt = 194k USD (from shortTermDebt, last quarter)
Debt = 77.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 13.7m
Net Debt = 48.3m USD (calculated: Debt 77.7m - CCE 29.4m)
Enterprise Value = 467.4m USD (419.1m + Debt 77.7m - CCE 29.4m)
Interest Coverage Ratio = -7.63 (Ebit TTM -30.8m / Interest Expense TTM 4.04m)
EV/FCF = -14.94x (Enterprise Value 467.4m / FCF TTM -31.3m)
FCF Yield = -6.69% (FCF TTM -31.3m / Enterprise Value 467.4m)
FCF Margin = -74.01% (FCF TTM -31.3m / Revenue TTM 42.3m)
Net Margin = -81.76% (Net Income TTM -34.6m / Revenue TTM 42.3m)
Gross Margin = 62.61% ((Revenue TTM 42.3m - Cost of Revenue TTM 15.8m) / Revenue TTM)
Gross Margin QoQ = 63.58% (prev 62.24%)
Tobins Q-Ratio = 5.39 (Enterprise Value 467.4m / Total Assets 86.7m)
Interest Expense / Debt = 5.20% (Interest Expense 4.04m / Debt 77.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -24.4m (EBIT -30.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.73 (Total Current Assets 48.7m / Total Current Liabilities 10.3m)
Debt / Equity = 7.21 (Debt 77.7m / totalStockholderEquity, last quarter 10.8m)
Debt / EBITDA = -1.76 (negative EBITDA) (Net Debt 48.3m / EBITDA -27.4m)
Debt / FCF = -1.54 (negative FCF - burning cash) (Net Debt 48.3m / FCF TTM -31.3m)
Total Stockholder Equity = 18.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -46.21% (Net Income -34.6m / Total Assets 86.7m)
RoE = -188.1% (Net Income TTM -34.6m / Total Stockholder Equity 18.4m)
RoCE = -44.93% (EBIT -30.8m / Capital Employed (Equity 18.4m + L.T.Debt 50.2m))
RoIC = -32.68% (negative operating profit) (NOPAT -24.4m / Invested Capital 74.5m)
WACC = 12.15% (E(419.1m)/V(496.8m) * Re(13.64%) + D(77.7m)/V(496.8m) * Rd(5.20%) * (1-Tc(0.21)))
Discount Rate = 13.64% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 91.56 | Cagr: 7.35%
[DCF] Fair Price = unknown (Cash Flow -31.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -2.66 | # QB: -3
Revenue Correlation: 98.89 | Revenue CAGR: 24.26% | SUE: -4.0 | # QB: -1
EPS current Quarter (2026-09-30): EPS=-0.32 | Chg30d=+2.57% | Revisions=-50% | Analysts=2
EPS current Year (2026-12-31): EPS=-1.30 | Chg30d=+1.38% | Revisions=-50% | GrowthEPS=-45.0% | GrowthRev=+32.5%
EPS next Year (2027-12-31): EPS=-1.20 | Chg30d=-7.98% | Revisions=-50% | GrowthEPS=+8.4% | GrowthRev=+15.4%
[Analyst] Revisions Ratio: -75% (up=0, down=9)